Sierra Leone vs Tajikistan: Access to anti-retroviral drugs, female
Sierra Leone
95.0%
in 2024
Tajikistan
95.0%
in 2024
Sierra Leone rank
19th
Tajikistan rank
19th
Access to anti-retroviral drugs, female over time
- Sierra Leone
- Tajikistan
How they compare
Sierra Leone currently reports 95.0% against 95.0% in Tajikistan, a difference of 0.0%.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Tajikistan ahead.
Sierra Leone ranks 19th and Tajikistan ranks 19th of 141 countries.
Across the 3 decades both report, Sierra Leone averaged higher in 1 and Tajikistan in 2.
Head to head by decade
| Decade | Sierra Leone | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.5% | 0.7% | 0.8% | Sierra Leone |
| 2010s | 28.4% | 29.8% | 1.4% | Tajikistan |
| 2020s | 80.4% | 83.4% | 3.0% | Tajikistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Sierra Leone or Tajikistan?
- Sierra Leone, at 95.0% against 95.0% in Tajikistan as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Sierra Leone and Tajikistan?
- 0.0%, with Sierra Leone ahead.
- How many years of comparable data are there for Sierra Leone and Tajikistan?
- 25 years are reported by both, from 2000 to 2024.
- How do Sierra Leone and Tajikistan rank globally for access to anti-retroviral drugs, female?
- Sierra Leone ranks 19th and Tajikistan ranks 19th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.